NCT07368803 — Yifan Wang neoantigen vaccine trial
Evaluation of the Safety, Tolerability and Efficacy of iNeo-Vac-R01, an Individualized mRNA Therapeutic Technology Based on Tumor Neoantigens, for Adjuvant Treatment in Patients With Biliary Malignant Tumors After Radical Resection
Registry record
| Registry ID | NCT07368803 ↗ |
|---|---|
| Lead sponsor | Yifan Wang |
| Collaborators | Hangzhou Neoantigen Therapeutics Co., Ltd. |
| Phase | Phase 1/2 |
| Status | Recruiting |
| Indication | Biliary Malignant Tumors |
| Enrollment | 20 participants (target) |
| Start date | 2025-09-11 |
| Primary completion | 2027-09-30 (est.) |
| Last registry update | 3 Feb 2026 |
Every field above is mirrored from the study record on ClinicalTrials.gov (NCT07368803), which the sponsor maintains and which carries the full protocol summary, eligibility criteria, sites and contacts. No neoantigen vaccine is approved anywhere yet — every program here is investigational, and inclusion is not an endorsement. See the methodology for how the tracker is built.
Where this fits
Daily coverage of the modality, tumor type and players this study touches:
Related trials
FAQ
What phase is NCT07368803?
NCT07368803 (Evaluation of the Safety, Tolerability and Efficacy of iNeo-Vac-R01, an Individualized mRNA Therapeutic Technology Based on Tumor Neoantigens, for Adjuvant Treatment in Patients With Biliary Malignant Tumors After Radical Resection) is registered on ClinicalTrials.gov as Phase 1/2, sponsored by Yifan Wang.
Is NCT07368803 recruiting?
As of the 2026-02-03 registry update, NCT07368803 is listed as "Recruiting". Eligibility criteria, study sites and contacts are maintained by the sponsor on the ClinicalTrials.gov record.
Who is running NCT07368803?
The lead sponsor is Yifan Wang. Collaborators: Hangzhou Neoantigen Therapeutics Co., Ltd..
What condition does NCT07368803 study?
The registered condition is Biliary Malignant Tumors. Primary completion is listed as 2027-09-30 (estimated).
Are results available for NCT07368803?
neoag.ai mirrors the registry's factual fields — sponsor, phase, status and dates — and does not publish trial results. Any posted results, publications, or outcome measures appear on the ClinicalTrials.gov record for NCT07368803.
Back to the full neoantigen vaccine trial tracker — 107 studies, refreshed daily from ClinicalTrials.gov. Background: primer, glossary, and the companies landscape.